Thermo Fisher Scientific, Inc. (NYSE:TMO) 42nd Annual J.P. Morgan Healthcare Conference January 9, 2023 11:15 AM ET Company Participants Marc Casper – Chief Executive Officer Conference Call Participants Rachel Vatnsdal – J.P. Morgan Rachel Vatnsdal Perfect. Good morning everyone. This is Rachel Vatnsdal from the Life Science Tools and Diagnostics team here at J.P. Morgan. I'm joined on stage by Marc Casper, CEO of Thermo Fisher. So as we typically do, this is going to be a 40 minute session. First of it, h ...

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO) (“Thermo Fisher”), the world leader in serving science, announced that its wholly owned subsidiary, Orion Acquisition AB (the “Buyer”), has extended the expiration time of the offering period of its previously announced tender offer (the “Offer”) to acquire all of the outstanding common shares (“Shares”) and all of the outstanding American Depositary Shares, each representing one Share (“ADSs” and, together with the Shares, the “Offe ...

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that Marc N. Casper, chairman, president and chief executive officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024, at 11:15 a.m. (EST). You can access the webcast of the presentation via the Investors section of our website, www.thermofisher.com. About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in servi ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended September 30, 2023 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 THERMO FISHER SCIENTIFIC INC. (Exact name of Registrant as specified in its charter) Delaware 04-2209186 (State of incorporation) (I.R.S. Employer Identification No.) 168 Third Avenue Waltham, Mas ...

Thermo Fisher Scientific Inc. (NYSE:TMO) Q3 2023 Earnings Call Transcript October 25, 2023 8:30 AM ET Company Participants Rafael Tejada - VP of IR Marc Casper - Chairman, President and CEO Stephen Williamson - SVP and CFO Conference Call Participants Jack Meehan - Nephron Research Dan Brennan - TD Cowen Derik de Bruin - Bank of America Rachel Vatnsdal - J.P. Morgan Puneet Souda - Leerink Partners Eve Burstein - Bernstein Operator Good morning, ladies and gentlemen, and welcome to the Thermo Fisher Scientif ...

Thermo Fisher Scientific Inc. (NYSE:TMO) Morgan Stanley 21st Annual Global Healthcare Conference September 13, 2023 8:50 AM ET Company Participants Marc Casper - Chairman, President and Chief Executive Officer Conference Call Participants Tejas Savant - Morgan Stanley Tejas Savant Hey, everyone. Good morning. Welcome to Day Three of the Morgan Stanley Healthcare Conference. I'm Tejas Savant and I cover the Life Science Tools and Diagnostics sector at Morgan Stanley. Before we kick it off, just some importan ...

Summary of Thermo Fisher Scientific Inc. Conference Call Company Overview - **Company**: Thermo Fisher Scientific Inc. (NYSE:TMO) - **Industry**: Life Sciences and Biotechnology - **Key Participants**: Marc Casper (Chairman, President, and CEO), Mattias Häggblom (Handelsbanken) Core Points and Arguments 1. **Company Transformation**: Thermo Fisher has evolved from a technology-focused company to one that prioritizes customer success, significantly increasing its workforce from 12,000 to over 125,000 employees since 2001, with a current focus of approximately 80% on services and consumables and 20% on products [5][6][7] 2. **Investment in R&D**: The company invests about $1.5 billion annually in R&D, supporting significant scientific advancements and maintaining a strong intellectual property base [4][12] 3. **Role in Life Sciences**: Thermo Fisher positions itself as a leader in the life sciences industry, contributing to advancements in precision medicine, advanced materials, and supporting the development of new therapies for diseases such as cancer and Alzheimer's [7][10][11] 4. **Innovation in Technology**: The launch of the Orbitrap Astral mass spectrometry technology is highlighted as a significant advancement, enabling faster and more sensitive protein research [16][17][18] 5. **Cell and Gene Therapy**: The company is committed to supporting the development of cell and gene therapies, focusing on reducing costs to make these treatments more accessible to patients [19][20] 6. **Customer Relationships**: Thermo Fisher emphasizes the importance of maintaining strong partnerships with customers, ensuring they feel supported and not trapped by their business model [21][22][23] 7. **Market Dynamics in China**: The company acknowledges recent challenges in the Chinese market, attributing them to business confidence and GDP growth issues rather than specific industry problems. Long-term prospects remain positive, with China expected to be a fast-growing market for life sciences [24][26][27][30] 8. **Capital Deployment Strategy**: Thermo Fisher plans to deploy approximately $75 billion over the next five years for M&A, repurchases, and dividends, focusing on value creation rather than transaction size [31][33] 9. **CRO and CDMO Expansion**: The rationale behind entering the CRO space with PPD is to enhance capabilities and scale, building on previous successes in the CDMO sector [34][35][36] 10. **Importance of Software**: The integration of software and digital capabilities is crucial for the company, enhancing user experience and data processing in their billion-dollar instrument business [40][41] Additional Important Insights - **Response to COVID-19**: Thermo Fisher's rapid response during the pandemic, including the development of qPCR tests, showcased the company's agility and commitment to innovation [15][14] - **Long-term Vision**: The leadership expresses optimism about the future, focusing on continuous improvement and the potential for significant advancements in life sciences [8][10] - **Geopolitical Considerations**: While acknowledging geopolitical tensions, the company remains focused on the long-term growth potential in various markets, including China [27][30] This summary encapsulates the key insights and strategic directions discussed during the conference call, reflecting Thermo Fisher Scientific's commitment to innovation, customer success, and market leadership in the life sciences industry.

Company Participants Marc Casper - Chairman, President and Chief Executive Officer Conference Call Participants Dan Arias - Stifel Dan Brennan - TD Cowen Rachel Vatnsdal - JPMorgan Operator I would now like to introduce our moderator to the call, Mr. Rafael Tejada, Vice President of Investor Relations. Mr. Tejada, you may now begin the call. Good morning, and thank you for joining us. On the call with me today is Marc Casper, our Chairman, President and Chief Executive Officer, and Stephen Williamson, Senio ...

Thermo Fisher Scientific Inc. (NYSE:TMO) Bernstein 39th Annual Strategic Decisions Conference Call May 31, 2023 11:00 AM ET Company Participants Marc Casper - Chairman, President and Chief Executive Officer Conference Call Participants Eve Burstein - Bernstein Eve Burstein All right. Good morning, everyone. Let's go ahead and get started. My name is Eve Burstein, and I'm a new analyst at Bernstein. No relation, even though the names sound similar. Pre-launch, we'll be launching on US life science tools and ...

Thermo Fisher Scientific Inc. (NYSE:TMO) BofA Securities 2023 Healthcare Conference Call May 10, 2023 11:00 AM ET Company Participants Marc Casper - Chairman, President and Chief Executive Officer Conference Call Participants Derik Bruin - Bank of America Securities Operator Abrupt start Â…2023 Healthcare Conference coming to live from the Encore in Las Vegas. Kicking off our session today is Thermo Fisher Scientific. And with us is Marc Casper, Chairman, President and CEO. I'm Derik De Bruin, the Senior Li ...